Scarica l'app Stockscreener
2.20
0.00%
0.00
Dopo l'orario di chiusura:
2.23
0.03
+1.36%
Precedente Chiudi:
$2.20
Aprire:
$2.21
Volume 24 ore:
165.09K
Relative Volume:
0.94
Capitalizzazione di mercato:
$6.66M
Reddito:
-
Utile/perdita netta:
$-31.88M
Rapporto P/E:
-2.9333
EPS:
-0.75
Flusso di cassa netto:
$-25.20M
1 W Prestazione:
-3.93%
1M Prestazione:
+2.80%
6M Prestazione:
-75.24%
1 anno Prestazione:
-91.54%
Intervallo 1D:
$2.15
$2.25
Intervallo di 1 settimana:
$2.144
$2.36
Portata 52W:
$2.05
$26.76
In 8 Bio Inc Stock (INAB) Company Profile
Nome
In 8 Bio Inc
Settore
Industria
Telefono
(646) 600-6438
Indirizzo
EMPIRE STATE BUILDING, NEW YORK
Confronta INAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
2.20 | 7.89M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-03-18 | Iniziato | Laidlaw | Buy |
| 2022-08-30 | Iniziato | H.C. Wainwright | Buy |
In 8 Bio Inc Borsa (INAB) Ultime notizie
Why Levi Strauss Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Layoff Tracker: Pacira Cuts 8% of San Diego Staff After Improving Manufacturing Efficiencies - BioSpace
Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors - GlobeNewswire
Pre-market Movers: CLDI, BMGL, PROK, RXST... - RTTNews
KALA BIO Announces Completion of Enrollment in CHASE - GlobeNewswire
Cizzle Bio Submits NIH Grant Proposal with Premier Research Institutions to Advance Biomarker Blood Test for Lung Cancer - Yahoo Finance
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma - Yahoo Finance
Clinical-Stage Biotech INmune Bio Secures $19M Through Strategic Share Offering - Stock Titan
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Clinical-Stage Immunology Company INmune Bio Secures $19M from Healthcare Investors at Market Price - Stock Titan
Major Alzheimer's Treatment Milestone: INmune Bio Reveals Phase 2 Trial Results Next Week - Stock Titan
ANVS gains NYSE approval of compliance plan, delisting risk eased | ANVS SEC FilingForm 8-K - Stock Titan
Global Protein Expression Market to Observe Growth at a CAGR of ~8% by 2032 | DelveInsight - GlobeNewswire
Nuvation Bio: A Justified Fall Based On Post-Marketing Requirements (NYSE:NUVB) - Seeking Alpha
U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer - Quantisnow
Breakthrough: New Drug Reduces Alzheimer's Risk After Brain Injury, DoD-Backed Study Shows - Stock Titan
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial - GlobeNewswire Inc.
European Launch: TELA Bio's Natural Hernia Repair Device Shows 98.8% Success Rate - Stock Titan
TELA Bio Appoints Jeffrey Blizard as President - GlobeNewswire
Pre-market Movers: ALZN, HCTI, REVB, NTLA... - RTTNews
KALA BIO to Present at Jefferies Global Healthcare Conference - GlobeNewswire
Analysts Set Cabaletta Bio, Inc. (NASDAQ:CABA) Price Target at $20.33 - MarketBeat
Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis - GlobeNewswire
Global Immunoprecipitation Market Set to Grow at a CAGR of 6-8%: Key Drivers and Challenges by 2029 - PharmiWeb.com
DNA Polymerase Market to Grow at 6–8% CAGR Driven by Genomics, PCR, and CRISPR Technologies by 2029 - PharmiWeb.com
GRI Bio Presents Positive Pre-Clinical Data Demonstrating - GlobeNewswire
Caisse Française de Financement Local: EMTN 2025-8 SOCIAL - The Manila Times
Protagenic Therapeutics Completes Acquisition of Phytanix Bio - TipRanks
Dimensional Fund Advisors LP Sells 592,968 Shares of bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
KALA BIO: Q1 Earnings Snapshot - The Washington Post
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Raymond James Financial Inc. Takes Position in 8×8, Inc. (NASDAQ:EGHT) - Defense World
INmune Bio Sets Stage for Key Biotech Insights at RBC Healthcare Conference Next Week - Stock Titan
Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025 - MSN
INmune Bio, Inc. (NASDAQ:INMB) Q1 2025 Earnings Call Transcript - Insider Monkey
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation - GlobeNewswire
TELA Bio, Inc. (NASDAQ:TELA) Q1 2025 Earnings Call Transcript - Insider Monkey
8 Best Medical Simulators On Steam, Ranked - Game Rant
Nuvation Bio Inc. (NUVB): Among Billionaire David Abrams’ Stock Picks with Huge Upside Potential - Yahoo Finance
bluebird bio, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your RightsBLUE - ACCESS Newswire
Shareholders that lost money on bluebird bio, Inc. (BLUE) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update - Yahoo Finance
TELA Bio Reports First Quarter 2025 Financial Results - Yahoo Finance
GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - Yahoo Finance
TELA Bio Inc (TELA) Q1 2025 Earnings Report Preview: What to Expect - Yahoo Finance
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) - Yahoo Finance
INmune Bio Inc (INMB) Q1 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
TELA Bio Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Instil Bio Inc expected to post a loss of $2.59 a shareEarnings Preview - TradingView
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases - GlobeNewswire
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th - The Manila Times
In 8 Bio Inc Azioni (INAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):